Author

Joseph van de Wiel

Observed names: J. van de Wiel, Joseph van der Wiel, van de Wiel, J.

Institutions: Cancer Research UK Clinical Trials Unit, University of Birmingham

Observed institutions: University of Warwick, Cancer Research UK Clinical Trials Unit, University of Birmingham

ORCID: 0000-0003-3523-2672

Observed ORCID: 0000-0003-3523-2672

OpenAlex ID: A5035591788

Connexin26 mediates CO2-dependent regulation of breathing via glial cells of the medulla oblongata

2020 · Joseph van de Wiel, Louise Meigh, et al. · Communications Biology · 50

Analyzing the brainstem circuits for respiratory chemosensitivity in freely moving mice

2022 · Amol Bhandare, Joseph van de Wiel, et al. · eLife · 24

Altered CO2 sensitivity of connexin26 mutant hemichannels in vitro

2016 · Elizabeth de Wolf, Joseph van de Wiel, et al. · Physiological Reports · 23

Pos0094 Pharmacodynamic Activity of Jnj-67484703 in Rheumatoid Arthritis, Ulcerative Colitis and Sjogren's Disease (paris): Results of a Phase Ii Proof of Biology Trial

2025 · B.A. Fisher, J. van de Wiel, et al. · Annals of the Rheumatic Diseases · 6

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

2026 · Nicholas David James, Joseph van de Wiel, et al. · Journal of Clinical Oncology · 2

Author response: Analyzing the brainstem circuits for respiratory chemosensitivity in freely moving mice

2022 · Amol Bhandare, Joseph van de Wiel, et al. · eLife · 1

Towards an understanding of the role of Connexin26 in breathing

2026 · Joseph van de Wiel · Warwick Research Archive Portal (University of Warwick)

P117 Pharmacodynamic activity of JNJ-67484703 in rheumatoid arthritis, ulcerative colitis and Sjogren’s disease: results of a phase II proof of biology trial

2026 · Benjamin A Fisher, Joseph van der Wiel, et al. · Rheumatology

Feasibility and safety results from RAD-IO: A multi-stage trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer.

2025 · Nicholas David James, Joseph van de Wiel, et al. · Journal of Clinical Oncology

Works count: 10

Citation count: 106

H-index: 4

I10-index: 3